Centrifuge is cost effective for separations where the recovery of secreted proteins is desired, contract manufacturers of vaccines, mammalian cell based therapies, and filamentous fungi products
With the introduction of the APD class of centrifuges, contract manufacturing organisations (CMOs) are reducing capital expenditures on downstream equipment by applying this novel technology platform across their spectrum of biotech separation applications.
Ideal for a multitude of biopharm separations where the recovery of secreted proteins is desired, contract manufacturers of vaccines, mammalian cell based therapies, and filamentous fungi products are making the APD an integral component of their equipment arsenal.
A modern version of the traditional tubular bowl centrifuge, the APD incorporates an automatic piston that totally discharges the solids phase from the centrifuge bowl.
Unlike existing disc centrifuge technologies, the solids exit the APD as a dry-paste in a form that is easily transferred or reconstituted for further processing.
Combining low shear flow-path features and rotational speeds from 0-20,000G, the multi-purpose APD centrifuge is designed to address the needs of laboratories and industrial biotech separation processes.
The machine offers validated CIP/SIP systems, thermal control, vacuum systems, and PLC controls for processing flexibility.
Celeros APD centrifuges are suitable for reactor volumes from 10-10,000 litres.
